PATENT CLAIM ANALYSIS

Application Number: 16224450
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "158100"]

Abstract:
This invention relates to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers (CXCR4-GPCR heteromers) associated with cancers, where CXCR4 forms a functional heteromer with other G protein-coupled receptors (GPCRx). More specifically, this invention relates to GPCRx that form heteromers with CXCR4, which upon co-stimulation with CXCR4 agonists and GPCRx agonists leads to enhanced signaling downstream of CXCR4. This invention also provides for the use of inhibitors of the interacting GPCR partner of the CXCR4-GPCRx heteromer or CXCR4-GPCRx heteromer-specific inhibitors including inhibitors of the formation of the CXCR4-GPCRx heteromer and CXCR4-GPCRx heteromer-specific antibodies, and in the diagnosis and/or therapy for cancer.

Claim (Index 189):
The method of suppressing of  claim 188 , wherein the CXCR4-HRH1 heteromer has two or more of the following characteristics:\n 1) the CXCR4-HRH1 heteromer components in a cell colocalize and physically interact, either directly or via intermediate proteins acting as conduits for allosterism, as determined via one or more of the following: a co-internalization assay, a colocalization assay, in situ hybridization, immunohistochemistry, immunoelectron microscopy, a proximity-based assay, a co-immunoprecipitation assay, enzyme-linked immunosorbent assay (ELISA), flow cytometry, RNAseq, qRT-PCR, microarray, or a fluorescent animal assay; 2) an enhanced amount of calcium mobilization, such that:\n a) either CXCR4 or HRH1 in an individual protomer context in a cell, upon co-stimulation with CXCL12 and a selective HRH1 agonist, results in a calcium mobilization amount that is equal to or less than the sum of calcium mobilization amounts resulting from single agonist stimulation with either the CXCL12 or the HRH1 agonist; and \n b) the CXCR4-HRH1 heteromer exhibits an enhanced calcium mobilization upon co-stimulation with the CXCL12 and the selective HRH1 agonist relative to the sum of calcium mobilization amounts resulting from single agonist stimulation with either the CXCL12 or the selective GPCRx agonist; \n as determined via a calcium mobilization assay; or 3) a CXCR4-HRH1 heteromer-selective reagent:\n i) alters heteromer-specific properties of the CXCR4-HRH1 heteromer in the cell; \n ii) alters heteromer-specific function of the CXCR4-HRH1 heteromer in the cell; \n iii) alters heteromer-specific properties of the cell containing the CXCR4-HRH1 heteromer; or \n iv) decreases cancer progression of the cell containing the CXCR4-HRH1 heteromer.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 98.0
- Lexical Diversity: 1.87302
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15007002', '11698291', '14289712', '13639864', '13806929']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7622075765283203
- 35 USC 102 Novelty (BERT): 0.5244917704757294
- Combined Prediction Score: 0.7384359959230612
- Mean Citation Score: 279.291308
- Max Citation Score: 297.03824
- Similarity Product: 176.1910706689262

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test